These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 15960147

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 3. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
    Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.
    J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.
    Ren Fail; 2012 Aug; 34(3):297-303. PubMed ID: 22251408
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S.
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [Abstract] [Full Text] [Related]

  • 8. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F, Yudd M.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [Abstract] [Full Text] [Related]

  • 9. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [Abstract] [Full Text] [Related]

  • 10. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, Mohamad S, Goh BL, Shah S, Seman MR, Vaithilingam I, Ghazalli R, Rahmat K, Shaariah W, Ching CH, Oral Paricalcitol in ESRD Study Group.
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [Abstract] [Full Text] [Related]

  • 11. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [Abstract] [Full Text] [Related]

  • 12. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
    Koc H, Hoser H, Akdag Y, Kendir C, Ersoy FF.
    Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
    [Abstract] [Full Text] [Related]

  • 13. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
    Alghareeb A, Sabry A, Bawadekji H, Alsaran K.
    Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
    Webb NJA, Lerner G, Warady BA, Dell KM, Greenbaum LA, Ariceta G, Hoppe B, Linde P, Lee HJ, Eldred A, Dufek MB.
    Pediatr Nephrol; 2017 Jul; 32(7):1221-1232. PubMed ID: 28332096
    [Abstract] [Full Text] [Related]

  • 15. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
    Sharma A, Ketteler M, Marshall TS, Khan SS, Schumock GT.
    J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P, Kovarik J, Klauser-Braun R, Graf H, Müller HW, Veres A, Seidinger S, Ketteler M.
    Nephron Clin Pract; 2014 Sep; 126(1):39-50. PubMed ID: 24458019
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.
    Martin KJ, González E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S57-63. PubMed ID: 11689389
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A, Marshall TS, Khan SS, Johns B.
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.